Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.

• Status: Completed
• Trial end date: 2010-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether investigational study drug, AG-013736, and gemcitabine are effective in the first-line treatment of advanced pancreatic cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Axitinib; Gemcitabine

Criteria

Inclusion Criteria:

• Histologically or cytologically confirmed, metastatic or locally-, advanced pancreatic adenocarcinoma not amenable to curative resection.

• Adequate renal, hepatic and bone marrow function.

• Performance status 0 or 1.

Exclusion Criteria:

• Prior treatment with any systemic chemotherapy for metastatic disease.

• Prior treatment with gemcitabine, AG-013736, or other vascular endothelial growth factor inhibitors.

• Current or recent bleeding, thromboembolic event and or use of a thrombolytic agent.

• Inability to take oral medication.